Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pierre Fabre

EU flag

Baxalta’s rare blood cancer drug Oncaspar approved in Europe

First EU-wide licence for the acute lymphoblastic leukaemia treatment

- PMLiVE

UCB wins European approval for epilepsy drug Briviact

Plans first launches within weeks

EU flag

Biogen-Samsung’s Enbrel biosimilar cleared for EU marketing

The companies plan to launch the treatment in the coming weeks

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

Roche Basel Switzerland

Roche gets EU green light for Cotellic

Approved in combination with Zelboraf for melanoma

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

New EC health director general takes office

XavierPrats Monné will report to health commissioner Dr Vytenis Andriukaitis

- PMLiVE

EU green light for Novartis’ skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links